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Iron chelation with DFO has dramatically improved the length of life for bfTM patients.1 However, ironfmediated cardiac toxicity remains the leading 
cause of death in bfTM patients starting in the second 
decade and increasingly thereafter.2 This high mortality 
in bfTM patients on DFO monotherapy results from a 
number of factors. Administration of DFO is uncomf
fortable and lengthy and there is poor compliance.3f5 
Subcutaneously administered DFO proved to be less 
effective in clearing cardiac iron loading compared with 
DFP.6,7 Longfterm outcome studies have correlated 
liver iron concentrations and high ferritin values with 
a subsequent risk of cardiac iron toxicity and considf
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BACKGROUND AND OBJECTIVES: cardiac events and death are not uncommon in adults with b-thalassemia 
(b-tm) taking deferoxamine (dfo) monotherapy because of poor compliance and possibly the less effectiveness 
of dfo in controlling cardiac iron overload. We sought to assess compliance with dfo, the percentage of shift 
to other iron chelators, and the occurrence of cardiac siderosis, and cardiac events and death in b-tm patients 
on dfo monotherapy. 
DESIGN AND SETTING: prospective, observational, 10-year follow-up of patients attending ain shams 
thalassemia unit, cairo, egypt.
METHODS: for all b-tm patients aged 2-18 years attending the unit during January 1998 and taking dfo, we 
recorded all cardiac events (whether fatal or not) during January 2008. all patients still on dfo monotherapy 
and with a normal eKG and not showing symptoms or signs suggestive of heart failure (hf) were evaluated for 
cardiac siderosis by t2*. 
RESULTS: of 412 patients, only 126 (31%) were still taking dfo monotherapy (only 43% of those were compli-
ant), 136 were taking combined dfo and deferiprone (dfp), 72 were taking dfp and 32 were taking deferasirox 
(dfX). twenty-one were lost follow-up and 25 died (10 cardiac). eight of ten cardiac deaths and 12 of 15 non-car-
diac deaths were in the dfo monotherapy group. those taking dfo monotherapy with no hf and left ventricular 
ejection fraction (lVef) by t2* >56% had a median age of 19 years and 56% were males; cardiac t2* was <20 
ms in 30 (22%); 10-20 ms in 20 (14.7%) and <10 ms in 10 (7.3%). lVef ranged from 58%-76 % (median 64%). 
forty percent of t2* patients <10 ms were compliant with dfo. 
CONCLUSION: fifty-eight percent of patients on dfo monotherapy were noncompliant, but even compliance 
did not prevent severe cardiac siderosis and most cardiac events (whether fatal or not) that occurred in the dfo 
monotherapy group. 
ered these parameters as surrogates for cardiac risk.8 
However, despite monitoring of the iron burden by 
these indices, cardiac failure and arrhythmias remain 
the leading cause of death in bfTM patients. Cardiac 
MRI measurements of the ironfsensitive relaxation 
time (T2*) show promise for identifying patients with 
preclinical myocardial iron overload.9 The value of liver 
iron concentration and serum ferritin as predictors of 
cardiac siderosis are questionable,10 while the value of 
cardiac T2* to tailor chelation is well established.11 The 
aim of this prospective study was to record compliance 
of Egyptian bfTM children and adults on DFO monof
therapy over the last decade and collect information on 
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the shift to other chelators, the occurrence of cardiac 
events and death over this period and to assess the def
gree of cardiac siderosis in bfTM patients with no heart 
failure who were still on DFO monotherapy.
PATIENTS AND METHODS 
DFO therapy in bfTM patients was first introduced at 
the Ain Shams Thalassemia Unit in 1982, and bfTM 
patients have started DFO at the age of 2 to 3 years. 
All patients aged 2f18 years (n=412) attending two 
centers—the Ain Shams Thalassemia Unit (n=392) 
and the Zagazig Center (n=20)—were followed up 
prospectively from 1998 for one decade to assess comf
pliance with DFO monotherapy and to determine the 
percentage of those who shifted to other chelators. All 
cardiac events, whether fatal or not, were also recorded. 
Chelation therapy consisted of deferoxamine used in a 
dose 20f40 mg/kg via a subcutaneous pump overnight. 
Compliance was considered good if DFO was received 
5f6 days/week (>250 days/year), only compliant if 3f
<5 days/week (150f<250 days/year), and poor if <3 
days/week (<150 days/year) or irregular (<50 days/
year). Deferiprone (DFP) was introduced in 2002 
orally in a dose 75f100 mg/kg/day, 7 days/week. The 
same doses were used in combination therapy (DFP 
7 days/week ±2f3 days DFO). Intensive combination 
therapy was DFP 100 mg/kg/d for 7 days/week and 
DFO 50 mg/kg/d 5f6 days/week. Deferasirox (DFX) 
was introduced in 2005 as a single morning oral dose 
20f30 mg/kg/day, 7 days/week.
In January 2008, all bfTM patients still taking DFO 
monotherapy and not showing symptoms or signs 
suggestive of heart failure and whose echocardiogram 
showed LVEF >56% were evaluated for cardiac siderof
sis by cardiac T2* at Cairo MRI Center and interpreted 
at the Royal Brompton Hospital, London, UK, and 
liver iron (R2) performed at Misr MRI Center and inf
terpreted at University of Western Australia, Crawley, 
Western Australia. Cardiac T2* and liver R2* data from 
the first scan for each patient are presented. Serum ferf
ritin was assessed every 6 months and the mean values 
of the last 2 years were included.
Diagnostic criteria included in the evaluation were:
• Heart failure: Dyspnea on rest or exercise and or  
    LVEF <56% by T2*
•  Arrhythmia: Complaint of palpitation and a stanff
dard 12–lead ECG with 24fhour recording showf
ing evidence of arrhythmia
• Nonfatal event: Nonfatal heart failure or arrhythmia.
• Magnetic resonance: One and half T scanner 
Table 1. Demographic data for deferoxamine subgroups by values of cardiac T2*.
Total T2* <10ms (n=10)
T2* 10-20ms 
(n=21)
T2* >20ms 
(n=95) P1 P2 P3
Age (years)
  range 13-21 15-30 12-28 
.0932 .1462 .1170
  Mean±SD 20.3±17.3 20.6±4.4 19.2±3.8
Male (n) 6 11 60
.69 .69 .69
Female (n) 4 10 35
LVEF (%)  
  range 58 – 73 60-76 58-79
.3004 .6026 .4323
  Mean±SD 66.2 ± 7.9 68 ±4.6 67.4±4.8
Liver iron concentration 
(mg/g)
  range 9.8-52 12.9-59.7  5-54  
.5612 .0165 .3027
  Mean±SD 29.4±12.6 32.6±14.7 11.9±25.3
Serum ferritin (ng/mL)    
  range 2343-9545 2139-9022 924- 9875
.5461 .1923 .0755
  Mean±SD 4577±2253.6 4116.6±1815.3 3613.4±1539.3
p1: The two-tailed p value of T2*<10ms versus   T2*10-20ms 
p2: The two-tailed p value of T2*10-20ms versusT2* >20ms 
p3: The two-tailed p value of T2*<10ms versus   T2* >20ms 
Significant values bolded
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   Siemens scanner using the standard technique
•  Cardiac T2*: Cardiacfgated, singlefbreathfhold,    
   8fecho sequence of a single midventricular short  
   axis slice, and data analysis was performed using 
  CMR tools and its plugfin in thalassemia tools
• Liver SDPA R2* (FerriScan)
Excluded from the study were bfTM patients not on 
DFO chelation until after the age 4 years and patients 
missed for follow up for more than 6 months during the 
study period of 10 years. Those on combination therapy 
and those on DFO monotherapy, but with LVEF <56% 
as assessed by T2* echocardiogram when evaluated for 
cardiac siderosis were excluded. All bfTM patients with 
T2* <10 milliseconds were shifted to combination DFP 
and DFO and those <6 milliseconds received intensive 
combination chelation therapy. 
SPSS for Windows, release 13.0 (SPSS Inc, USA) 
was used for data entry and analysis. All numeric varif
ables were expressed as mean and standard deviation 
(SD). A comparison of different variables in various 
groups was done using the t test and Mann Whitney test 
for normal and nonparametric variables respectively. The 
chifsquare test was used to compare frequency of qualitaf
tive variables among the different groups. The Spearman 
correlation test was used for correlating nonfparametric 
variables. For all tests a probability. Less than 0.05 was 
considered significant.13
RESULTS 
There were no differences in sex, age and serum ferritin 
by T2* level (<10, 10f20 and >20 milliseconds) (Table 
1). Only liver iron concentration (LIC) was significantly 
higher in the T2* 10f20 milliseconds group, but there 
was a lack of correlation between LIC and cardiac sidf
erosis as evidenced by cardiac T2* and liver R2* (Figure 
1). Unexpectedly, LVEF was not different in the three 
T2* subgroups, and there was no correlation between 
LVEF and cardiac siderosis (Figure 2). Only 18 patients 
had good compliance and 36 were compliant (included 
together as the compliant group (n=54, 43%), whereas 
poor compliance was observed in 44 (35%) and the least 
compliant was the irregular group (n=28, 22%).  Thirty 
percent of patients with T2* <10 milliseconds were eif
ther in good compliance (10%) or compliant (20%) on 
DFO where as 30% of patients with T2* 10f20 millisecf
onds were either in good compliance (10%) or compliant 
(20%) on DFO. Differences in iron overload (serum ferf
ritin, LIC) were highly significant in the different complif
ance groups (Table 2). The greatest difference was in the 
irregular group, which showed the heaviest iron overload, 
while T2* was longest in the compliant groups, but the 
difference was statistically insignificant; unexpectedly 
LVEF was not significantly different in the three complif
ance groups; it was highest in the patients on irregular 
DFO, but the difference was not statistically significant.
DISCUSSION
Since DFO was licensed in Egypt in 1982, a new era of 
thalassemia management began in our center. However, 
compliance after a few years was declining, with a good 
percentage noncompliant or irregular. About two def
cades later DFP was licensed in Egypt in 2000. A good 
percentage of bfTM patients shifted to the newly introf
duced oral chelator, but after publication of results of 
Table 2. Age, iron overload and LVEF by deferoxamine compliance.
Good  
compliance  
and compliant 
(n=54)
Poor
compliance     
(n=44)
Irregular 
compliance 
(n=28)
P1 P2 P3
Age (years)
mean±SD 19.4±3.2 18.9±4.1 19.3±4.1 .4994 .6878 .9035
T2* (ms)
mean±SD 28.9±11.3 25.3±9.8 26.1±10.9 .0994 .7475 .2848
LVEF (%)
mean±SD 67.1±4.8 66.3±5.5 68.7±4.7 .4440 .0606 .1534
Liver iron concentration 
(mg/g)
mean±SD
17.1±7.6 31.2±8.7 37.6±11.2 .0001 .0077 .0001
Serum ferritin (ngml) 
mean±SD 3080.6±890.8 3750.9±.1367.8 5114.3±2144.2 .0043 .0015 .0001
p1: The two-tailed p value for compliant versus poor compliance
p2: The two-tailed p value for poor compliance versus irregular compliance
p3: The two-tailed p value of compliant versus irregular compliance
 Significant values bolded
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better chelation with combination therapy, more patients 
shifted to combination therapy. In 2005, DFX was introf
duced to our patients and some patients shifted to the 
newer iron oral chelator. 
In this prospective study, after a decade of follow up, 
slightly less than 1/3 of the studied patients were still on 
DFO monotherapy, even though it is cheaper and there 
is more experience with it. Another onefthird of this cof
hort shifted to combination (DFO and DFP) and almost 
onefthird shifted to either DFP or DFX monotherapy. 
However, most of them (58%) taking DFO were either 
noncompliant or using irregularly because of its uncomf
fortable, painful administration by lengthy subcutaneous 
pump infusion.
Contrary to most reports,12,14 heavy liver iron overf
load occurred in most of our patients taking DFO monof
therapy, and almost 60% of the patients were poorly comf
pliant or irregularly compliant therapy and LICs were 
significantly higher. Even compliant patients appeared 
to have high median LIC (>14 mg/g), which is toxic to 
the liver. Patients who were in good compliance to DFO 
treatment had the best LIC; however, none had an LIC 
<2mg/g and only 20% had an LIC between 2f7 mg/g. 
There was also a lack of correlation between cardiac sidf
erosis and LIC.
The three available iron chelators have a different 
mode of action, efficacy and route of administration. 
Dosage and compliance are essential for optimum chef
lation. The recommended initial dose for DFX was 20 
mg/kg/day for patients receiving 2 packed red blood cell 
units/month and 10 or 30 mg/kg/day was recommended 
for patients receiving less or more frequent transfusions, 
respectively,15 while DFP was used in a dose of 75f100 
mg/kg. According to the degree of hemosiderosis, DFO 
was used in a dose 20f40 mg/kg/dose, using the subcutaf
neous pump overnight. Most patients in this study were 
following the same doses, while those with suboptimal 
chelation, increased transfusional requirements, or who 
had initiated transfusions earlier in life should be tested 
more frequently and have more intensive chelation.16
Over the decade, both cardiac events and death2, 12,15 
were commoner in the DFO monotherapy group comf
pared to the DFP group. In this prospective study, most 
cardiac events and death were recorded in the DFO 
monotherapy group, which may be explained by poor 
clearance of iron from the heart in patients with severe 
cardiac siderosis. Severe cardiac siderosis cannot be corf
rected easily by subcutaneous DFO infusion. Cardiac 
T2* magnetic resonance identifies patients at high risk of 
heart failure and arrhythmia from myocardial siderosis in 
thalassemia major and is superior to serum ferritin and 
LIC. Using cardiac T2* for the early identification and 
treatment of patients at risk is a logical means of reducing 
the high burden of cardiac mortality in myocardial sidf
erosis. Since 1999, there has been a marked improvement 
in survival in thalassaemia major in the UK, which has 
been mainly driven by a reduction in deaths due to carf
diac iron overload. The most likely causes for this include 
the introduction of T2* CMR to identify myocardial 
siderosis and appropriate intensification of iron chelation 
treatment, alongside other improvements.18
Cardiac and endocrine disorders are common sequelf
ae of iron overload in transfused thalassaemia patients. 
Combined chelation with DFO and DFP is well tolerf
ated and produces an additive/synergistic effect superior 
to either drug alone.19 Patients on combination therapy 
were less affected by cardiac problems.
This prospective study showed that in the cohort 
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Figure 1. Lack of correlation between T2* and liver iron 
concentration (r=0.23, p>.05).
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Figure 2. No significant correlation between LVEF and T2* ≤10 ms 
(r=0.15), >10-20 ms (r= 0.42), ≥20 ms (r=-0.92).
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on DFO monotherapy with no evidence of heart failf
ure (their upper age limit was less than 30 years with a 
median of 19 years), less than onefthird had cardiac T2* 
<20 milliseconds and 37.5% were compliant with DFO 
monotherapy. Onefthird of those with cardiac siderosis 
had T2*<10 milliseconds, which indicates moderately 
severe siderosis. Serum ferritin and LIC were higher in 
bfTM with T2* <20 milliseconds, but there was no corf
relation between these variables. Tanner et al showed a 
prevalence of myocardial iron overload (T2*<20 milf
liseconds) in 65% of thalassemia major in an age group 
ranging from (18f42 years, mean=30±5.3).20 In contrast 
to our study, only 28.9% were < 20 milliseconds, which 
may be attributed to the younger age group of median 
age 10 years and the inclusion of patients with compenf
sated heart. 
As determined by T2*, LVEF was not different in the 
three groups (T2* <10, 10f<20 and ≥ 20 milliseconds). 
However, since all enrolled patients had LVEF >56% 
as checked by ECHO (data not shown), nonsignificant 
differences were expected. Patients with T2*<10 milf
liseconds were considered to have severe iron overload 
and this category included most patients with nonsignifif
cantly reduced LVEF. 
The availability of two oral chelators, DFP and DFX, 
has reduced the need for the injectable chelator DFO and 
an additional benefit has been that DFP has been shown 
to be more cardioprotective than DFO.21,22 Recently, alf
ternate daily DFP and DFX was introduced.23 In anothf
er study, satisfaction was significantly better with DFX 
compared to DFO.24
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